1. Home
  2. GNFT vs CMPS Comparison

GNFT vs CMPS Comparison

Compare GNFT & CMPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GNFT
  • CMPS
  • Stock Information
  • Founded
  • GNFT 1999
  • CMPS 2020
  • Country
  • GNFT France
  • CMPS United Kingdom
  • Employees
  • GNFT N/A
  • CMPS N/A
  • Industry
  • GNFT Biotechnology: Biological Products (No Diagnostic Substances)
  • CMPS Biotechnology: Pharmaceutical Preparations
  • Sector
  • GNFT Health Care
  • CMPS Health Care
  • Exchange
  • GNFT Nasdaq
  • CMPS Nasdaq
  • Market Cap
  • GNFT 190.6M
  • CMPS 280.2M
  • IPO Year
  • GNFT 2019
  • CMPS 2020
  • Fundamental
  • Price
  • GNFT $3.75
  • CMPS $4.05
  • Analyst Decision
  • GNFT Strong Buy
  • CMPS Strong Buy
  • Analyst Count
  • GNFT 1
  • CMPS 6
  • Target Price
  • GNFT $13.00
  • CMPS $33.60
  • AVG Volume (30 Days)
  • GNFT 8.9K
  • CMPS 666.3K
  • Earning Date
  • GNFT 09-19-2024
  • CMPS 10-31-2024
  • Dividend Yield
  • GNFT N/A
  • CMPS N/A
  • EPS Growth
  • GNFT N/A
  • CMPS N/A
  • EPS
  • GNFT 0.47
  • CMPS N/A
  • Revenue
  • GNFT $86,225,222.00
  • CMPS N/A
  • Revenue This Year
  • GNFT $155.44
  • CMPS N/A
  • Revenue Next Year
  • GNFT N/A
  • CMPS N/A
  • P/E Ratio
  • GNFT $7.55
  • CMPS N/A
  • Revenue Growth
  • GNFT 175.45
  • CMPS N/A
  • 52 Week Low
  • GNFT $3.31
  • CMPS $3.86
  • 52 Week High
  • GNFT $6.42
  • CMPS $12.75
  • Technical
  • Relative Strength Index (RSI)
  • GNFT 29.68
  • CMPS 35.91
  • Support Level
  • GNFT $3.63
  • CMPS $3.86
  • Resistance Level
  • GNFT $3.94
  • CMPS $4.20
  • Average True Range (ATR)
  • GNFT 0.12
  • CMPS 0.28
  • MACD
  • GNFT 0.03
  • CMPS 0.00
  • Stochastic Oscillator
  • GNFT 0.69
  • CMPS 8.06

About GNFT GENFIT S.A.

Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of innovative medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.

About CMPS COMPASS Pathways Plc American Depository Shares

Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find better ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.

Share on Social Networks: